What Happens After TURBT? How Pathology Results and Follow-Up Cystoscopy Guide the Next Steps

The procedure itself takes an hour or so. The waiting takes longer. Most people who have a transurethral resection of bladder tumor are home the same day or the next morning, sore, passing pink-tinged urine and holding a discharge sheet that says a follow-up appointment will be arranged. What it rarely says is that the most consequential part of the operation is now happening in a laboratory, under a microscope, without them in the room.

That is the honest shape of the weeks ahead. After TURBT, pathology and follow-up do the real steering: a report describes what the tumor was and how deep it reached, and that description decides whether the next step is a single check-up camera test, a second trip to the operating room, or a longer conversation about treatment inside the bladder.

This explainer walks through that sequence in order, from the report to the surveillance schedule, so the phone call from the clinic makes sense when it comes.

What actually happens during and after TURBT, and why the pathology matters most

TURBT stands for transurethral resection of bladder tumor: a surgeon passes a thin telescope through the urethra, the tube that carries urine out of the body, and uses a small electrical loop to shave away the growth from the bladder lining, according to the NHS. There is no external cut. The tissue is collected and sent for examination, the raw area is sealed with heat, and a catheter often stays in place for a day or so to drain the bladder while it settles.

The surgeon can see the tumor’s size, shape and position. What the surgeon cannot see is how deep the cells have travelled into the bladder wall, or how abnormal they look up close. Those two questions, depth and appearance, are the ones that decide everything that follows, and only a pathologist can answer them. A pathologist is a physician who examines tissue under a microscope to diagnose disease.

This is why TURBT is described by the Mayo Clinic as both a diagnostic and a treatment procedure. It removes visible disease and, at the same time, produces the sample that stages it. The two jobs are done in one sitting, but they are judged at different times.

Think of the operation as the survey and the report as the map. A survey crew can measure what is on the surface; only the lab analysis shows what lies beneath it. Patients often understand the surgery to be the main event and the report an afterthought. In practice the order of importance is reversed. The resection buys time and information; the pathology decides how that time is used.

How long for bladder biopsy results after TURBT?

Most tissue reports come back within roughly one to two weeks, although MedlinePlus notes that biopsy results can take longer when extra tests are needed. For bladder tissue, that extra work usually means special stains that help distinguish surface disease from invasion, or a second pathologist reviewing a borderline slide. A delay of this kind is not a sign that something is wrong; it is a sign that the report is being made carefully.

Several steps happen in that interval. The tissue is fixed in preservative, embedded in wax, sliced thinner than a sheet of paper, stained and mounted. A pathologist then reads the slides, measures the depth of any invasion and assigns a grade. The report is typed, checked and released to the urologist, who reads it before deciding whether to phone, write or book a face-to-face visit.

Many hospitals discuss results in a multidisciplinary meeting, where urologists, pathologists, radiologists and oncologists review the case together. The NHS describes this team approach as standard for cancer care. It adds a few days but tends to produce a firmer plan.

Waiting is genuinely hard, and it helps to know what to expect from the clinic. Ask before discharge how results will be delivered, whether a results appointment is booked automatically, and who to call if nothing has been heard after the expected window. A named contact, usually a specialist nurse, is worth writing down.

One practical note: tissue that reaches the lab in fragments still yields a valid report, but very small or heavily cauterized fragments can limit what the pathologist can say about depth. That limitation, when present, will usually appear in the report and can itself shape the next step.

Reading the after-TURBT pathology report: stage, grade and the words that matter

Two headline findings sit at the heart of the report: stage and grade. Stage describes how far the tumor has grown into the layers of the bladder wall. Grade describes how abnormal the cells look compared with healthy bladder lining.

The bladder wall has an inner lining, a layer of connective tissue beneath it, and then the detrusor, the thick muscle that squeezes to empty the bladder. The Mayo Clinic explains staging in these terms. A tumor confined to the lining is labelled Ta. One that has reached the connective tissue but not the muscle is T1. Carcinoma in situ, often written CIS, is a flat, high-grade patch that sits within the lining rather than growing outward. Anything reaching the muscle is T2 or beyond, and is called muscle-invasive bladder cancer.

Ta, T1 and CIS together make up non-muscle-invasive bladder cancer. According to the NHS, the majority of bladder cancers, commonly quoted as roughly 7 in 10 at diagnosis, fall into this group, which is why so many TURBT reports lead to surveillance and bladder-sparing care rather than major surgery.

Grade is reported as low or high. Low-grade cells resemble normal cells and tend to recur without becoming dangerous; high-grade cells look disorganized and carry a greater chance of invading over time. A small high-grade tumor is generally taken more seriously than a larger low-grade one.

Other lines worth noticing include the size and number of tumors, whether there is lymphovascular invasion (cancer cells inside tiny blood or lymph vessels), and any unusual cell type, sometimes called variant histology. Each of these nudges the risk assessment and, with it, the follow-up plan.

Why the line about detrusor muscle deserves a second look

Somewhere in the report, often near the end, a sentence will say whether detrusor muscle is present in the specimen, or absent. It reads like a technical footnote. It is closer to the crux of the whole document.

A pathologist can only state that a tumor has not reached the muscle if there is muscle on the slide to examine. When the sample contains no muscle, the report can describe what was seen but cannot rule out invasion below it. The stage assigned is then provisional, a floor rather than a ceiling. This is the reason quality guidance for TURBT emphasizes taking a sample that includes the base of the tumor and some underlying muscle, as summarized in the treatment sections of the NHS and Mayo Clinic.

Absence of muscle does not automatically mean a poor resection. For a tiny, clearly superficial, low-grade papillary growth on a thin part of the bladder, surgeons sometimes deliberately avoid cutting deep, because the risk of perforating the wall outweighs the information gained. Context matters, and the surgeon’s operative note will usually explain it.

For high-grade T1 disease, the picture is different. Here the difference between ‘T1 with muscle present and uninvolved’ and ‘T1, no muscle sampled’ is the difference between reasonable confidence and an open question. This is one of the strongest reasons a urologist will recommend a second resection, discussed in the next section, before committing to a treatment pathway.

If the phrase is missing or unclear, it is entirely reasonable to ask the care team directly: was muscle present in my sample, and if not, does that change the plan? It is a precise question with a precise answer, and clinicians expect it.

Who is usually offered a second TURBT, and who is usually asked to wait

A second resection, sometimes called a re-resection or repeat TURBT, is a return to the operating room a few weeks after the first procedure to re-examine and re-sample the original tumor site. The NHS notes that people with high-risk non-muscle-invasive disease may be offered this further operation a few weeks after the first, and international urology guidance typically places it within about 2–6 weeks.

Three groups are most often offered it. The first is anyone with T1 disease, because residual tumor at the base is common and understaging, meaning the cancer is actually deeper than the first report showed, is a recognized risk. The second is anyone with high-grade disease whose specimen lacked detrusor muscle, for the reasons covered above. The third is anyone whose surgeon judged the first resection incomplete, for example because of bleeding, a very large tumor or a difficult position.

People with small, solitary, low-grade Ta tumors and a complete resection are generally not asked to return to the theater. For them, the added risk of anesthesia and bladder injury is not justified by the small chance of finding anything that would change management. They move directly to surveillance.

Timing matters in both directions. Operating too early, before the raw area has healed, makes the tissue harder to interpret; waiting too long delays any treatment that the second report might prompt. The window guidelines describe is a compromise between the two.

Frailty, other medical conditions and the person’s own wishes all feed into the decision. A re-resection is a recommendation, not a reflex, and the treating team weighs it case by case.

How risk groups turn after-TURBT pathology into a follow-up protocol

Once stage, grade, size, number and muscle status are known, urologists sort non-muscle-invasive disease into risk groups. The labels vary slightly between guideline bodies, but the logic is consistent and the NHS describes the same three tiers: low, intermediate and high risk. The group determines how often the bladder is checked and whether treatment is added to surveillance.

The table below summarizes the general pattern. It is illustrative, not a prescription; the treating team sets the actual schedule, and the Mayo Clinic notes that follow-up testing is often every 3–6 months for the first few years before spacing out.

Risk group	Typical pathology	Usual next steps	Cystoscopy pattern
Low	Single, small, low-grade Ta; first occurrence	Often a one-time chemotherapy instillation shortly after surgery, then surveillance	Early check at a few months, then a later check; discharge from surveillance possible if clear
Intermediate	Multiple or recurrent low-grade Ta, or larger tumors	Course of intravesical chemotherapy or BCG; surveillance	Regular checks for around five years, more frequent early on
High	High-grade Ta, any T1, CIS	Repeat TURBT commonly; BCG induction and maintenance; discussion of bladder removal for the very highest risk	Frequent checks for the first two years, then gradually spaced, often lifelong

The pattern reveals a principle: surveillance intensity tracks the chance of progression, not simply the chance of recurrence. Low-grade tumors return often but rarely turn dangerous, so a lighter schedule is safe. High-grade disease returns less predictably but with higher stakes, so the bladder is watched closely.

Risk grouping is a starting point rather than a verdict. Subsequent findings, response to treatment and a person’s overall health can move someone between tiers over time.

What a follow-up cystoscopy after TURBT is really like

Cystoscopy is the examination of the inside of the bladder with a thin, lighted camera passed through the urethra. Follow-up cystoscopies after TURBT are almost always done in an outpatient room with a flexible scope and a numbing gel rather than a general anesthetic, and MedlinePlus describes the procedure taking only a few minutes once the scope is in.

Here is the usual sequence. You empty your bladder, lie on an examination couch, and the area is cleaned. Anesthetic gel is placed into the urethra and given a moment to work. The flexible scope, roughly the width of a drinking straw, is guided into the bladder, which is filled with sterile fluid so the walls unfold and can be inspected. The clinician looks systematically at every surface, paying particular attention to the previous resection site, which often shows as a pale scar.

Discomfort is real but brief: pressure, an urge to urinate, and stinging as the scope passes. The Mayo Clinic notes that mild burning on urination and a little blood in the urine can follow for a day or two, and that drinking water afterwards helps. Some clinics use blue-light or enhanced imaging to make flat or early lesions more visible; where available, this is a technical addition rather than a different test.

Very often the clinician can tell you what they saw before you leave the room. A clear bladder means the next appointment is booked. A suspicious area may be photographed, biopsied in the same sitting if the equipment allows, or scheduled for a further TURBT under anesthetic.

Bringing someone along is sensible for the first few visits, less for physical support than because results conversations are easier to absorb with a second listener.

What else belongs in follow-up: urine tests, imaging and the upper tract

Cystoscopy is the backbone of surveillance, but it is not the whole skeleton. Three other elements appear in most follow-up plans, weighted according to risk.

Urine cytology is the first. A sample is examined under the microscope for abnormal cells shed from the lining, a test the Mayo Clinic lists among standard bladder cancer investigations. It is most useful for high-grade disease and CIS, where cells look distinctly abnormal, and much less reliable for low-grade tumors, which shed cells that closely resemble normal ones. A negative cytology therefore reassures more in a high-risk person than a low-risk one, and a positive result with a clear cystoscopy prompts a search elsewhere.

Imaging of the upper urinary tract is the second. The kidneys’ collecting systems and the ureters, the tubes carrying urine to the bladder, share the same lining as the bladder and can develop the same disease. A CT urogram, a contrast scan that outlines the whole urinary tract, is used at diagnosis and repeated at intervals for higher-risk disease, as the NHS describes. Low-risk disease rarely needs repeated imaging.

The third element is simply time with a clinician: a review of urinary symptoms, bleeding, and side effects of any treatment inside the bladder. Smoking cessation belongs in this conversation too. Tobacco is the leading modifiable cause of bladder cancer according to MedlinePlus, and continuing to smoke after diagnosis works against every other step in the plan.

Newer urine-based molecular markers exist and are being studied, but current guidance does not treat any of them as a replacement for cystoscopy. Where the evidence is still forming, the safest summary is that they may complement the camera; they do not retire it.

Can bladder cancer come back after TURBT? Recurrence versus progression

Yes, and frequently. The NHS states plainly that non-muscle-invasive bladder cancer has a high chance of returning, which is the entire reason follow-up cystoscopy exists. This fact unsettles people, so it helps to separate two words that clinicians use carefully and patients often hear as one.

Recurrence means a new tumor appears in the bladder lining, usually of the same stage and grade as before. For low-grade disease this is common and, in most cases, manageable: the growth is spotted at a scheduled check and removed with another outpatient resection or, for tiny lesions, sometimes treated in clinic. Many people with low-grade disease go through several such cycles over years without their situation fundamentally changing.

Progression means the disease has become more aggressive: a higher grade, a deeper stage, or spread beyond the bladder. This is the outcome surveillance and intravesical treatment are designed to catch early or prevent. It is far less common than recurrence, and the risk concentrates in high-grade and T1 disease, which is why those groups receive the most intensive follow-up.

Why does the bladder lining regrow tumors so readily? The prevailing explanation is a field effect: the same exposure, most often tobacco smoke carried in urine, has affected the entire lining, so cells in other areas can be primed to change. There is also the possibility that microscopic cells from the original tumor re-implanted elsewhere at the time of surgery, which is part of the rationale for placing chemotherapy into the bladder soon afterward.

Recurrence, then, is anticipated rather than exceptional. The plan assumes it might happen and is built to find it small.

Where intravesical treatment fits after TURBT

Intravesical treatment means placing a medicine directly into the bladder through a catheter, holding it there for a period, then passing it out. Because the drug bathes the lining rather than circulating through the body, whole-body side effects are limited. The NHS describes two broad approaches.

The first is intravesical chemotherapy, using medicines that damage rapidly dividing cells. For low- and intermediate-risk disease, a one-time instillation is often given shortly after TURBT, when the bladder still contains loose cells that could otherwise settle and regrow. Intermediate-risk disease may instead receive a course spread over several weeks. Typical effects are bladder irritation, urgency and burning for a day or two after each treatment.

The second is BCG, a weakened form of a bacterium originally developed as a tuberculosis vaccine. Placed in the bladder, it triggers a local immune reaction that helps the body recognize and attack abnormal cells. The NHS notes it is used mainly for high-risk non-muscle-invasive disease and CIS, as an initial course over several weeks followed, for many people, by maintenance treatments extending beyond a year. Flu-like symptoms, fatigue and bladder irritation after treatments are common; fever that persists is not, and is a reason to seek care.

These treatments reduce the chance of recurrence and, for BCG in high-risk disease, are intended to lower the chance of progression. They do not remove the need for cystoscopy; surveillance continues alongside them, with the treatment response itself becoming part of what the follow-up assesses.

Whether either is offered, and on what schedule, is a decision for the prescribing urologist based on the risk group, the person’s other health conditions and, where relevant, medication supply. Timelines above describe usual practice, not a commitment.

When the pathology shows muscle-invasive disease

Sometimes the report comes back T2 or higher: the tumor has reached the detrusor muscle. This is the finding that changes the conversation most, because muscle-invasive bladder cancer is treated as a disease of the whole bladder rather than its surface, and TURBT alone is not considered adequate treatment for it.

The immediate next step is staging beyond the bladder. The Mayo Clinic describes CT scans of the abdomen, pelvis and chest to look for spread to lymph nodes or other organs, and sometimes bone scans or MRI. Blood tests assess kidney function, which affects which treatments are safe. A repeat TURBT is not usually needed for staging at this point, though it is sometimes used when the extent of disease is unclear.

Treatment options are then discussed by the multidisciplinary team. The NHS describes the main approaches as radical cystectomy, the surgical removal of the bladder with reconstruction of a way to pass urine, often preceded by chemotherapy given into the bloodstream; or a bladder-preserving combination of maximal TURBT, radiotherapy and chemotherapy for people who are suitable and prefer to keep their bladder. Each has distinct trade-offs in recovery, long-term function and follow-up, and neither is right for everyone.

People in this situation often feel that the ground has shifted quickly. It has. Yet the fact that the diagnosis was made through TURBT means the disease was found and characterized, which is the precondition for any effective plan.

Second opinions are common and appropriate at this stage, and a good team will support one. What matters most is that the staging is complete and the options are explained in full before a decision is made.

How long does the bladder take to heal after TURBT? The first days and weeks

The raw area left by resection heals from its edges inward, much like a graze inside the mouth, and the NHS notes that most people are home the same day or after one night. The catheter, if one was placed, is usually removed before discharge or within a day or two, once the urine is running reasonably clear.

Blood in the urine is expected. In the first days it can be frankly pink or red, then it fades to a rust tint and often disappears, only to return briefly about a week or two later as the scab over the resection site lifts away. That second episode alarms people, but it is a normal stage of healing rather than a setback. Passing a few small clots is also common early on.

Burning, urgency and frequency come from an irritated bladder and generally ease over the first one to two weeks. Drinking plenty of fluid, unless the care team has advised otherwise, dilutes the urine and reduces stinging. Constipation is worth avoiding, since straining puts pressure on the healing wall.

Activity returns in steps. Walking is encouraged from the first day. The NHS advises avoiding heavy lifting and strenuous exercise for a few weeks, because a sudden rise in abdominal pressure can restart bleeding. Sexual activity and driving are usually fine once urine is clear and there is no discomfort, but individual advice varies and the discharge sheet should be followed.

Complete healing of the resection site is typically a matter of several weeks, which is why the first follow-up cystoscopy is scheduled around three months rather than sooner: by then, the scar is mature and any new growth stands out against it.

What people often get wrong about after-TURBT pathology and follow-up

The first misconception is that a clean-looking operation means a clean result. Surgeons can describe what they removed; only the microscope can say how deep it went or how aggressive it looks. A reassuring conversation in recovery is not the final word, and neither is a worrying one.

The second is that recurrence means treatment failed. For non-muscle-invasive disease, recurrence is the expected behavior of the lining, not a verdict on the surgeon or the patient. The measure of a good plan is whether recurrences are caught small and whether progression is avoided, not whether the bladder never grows another polyp.

Third, people assume a clear cystoscopy means surveillance can stop. Schedules taper for a reason: the risk of late recurrence falls but does not vanish, and for high-risk disease, guidance summarized by the NHS supports checks continuing for years. Skipping appointments because the last few were clear undoes the logic of the entire program.

Fourth, urine tests are sometimes treated as a substitute for the camera. Cytology misses many low-grade tumors, and no marker currently in use replaces direct visual inspection.

Fifth, a second TURBT is misread as a sign the first was done badly. In high-grade T1 disease it is standard practice, recommended precisely because even well-performed first resections can leave residual disease or understage the tumor.

Finally, some believe that feeling well is evidence of a healthy bladder. Early recurrences are usually silent. The whole point of scheduled cystoscopy is that it does not wait for symptoms to appear.

Questions to ask your care team

A results appointment moves quickly, and questions that felt obvious at home evaporate under fluorescent light. Writing a short list beforehand, and handing it over if speaking is hard, is a legitimate strategy. The following questions cover the decisions that matter most after TURBT.

• What stage and grade did the pathology show, and which risk group does that place me in?
• Was detrusor muscle present in the specimen? If not, does that change my plan?
• Do you recommend a second TURBT, and if so, roughly when?
• Will I be offered treatment inside the bladder? What is it intended to do, and what side effects should I expect?
• How often will I have cystoscopy in the first year, and how will that change over time?
• Will I need urine tests or scans of my kidneys and ureters as well, and how often?
• Who is my named contact, and how do I reach them between appointments?
• What symptoms should prompt me to call before my next scheduled visit?
• Is there anything about my other health conditions or medicines that affects these choices?
• Where can I read a copy of my pathology report?

Two habits make these conversations more useful. Ask for the answer in plain words first and the technical version second; both are valuable, in that order. And ask what the team would want to know if the result were their own, which tends to surface the points they consider most important.

Not every question will have a firm answer on the day, especially where a second resection or a team meeting is still pending. An honest ‘we will know more after the next step’ is a good sign, not a brush-off.

When to call your doctor

Some symptoms after TURBT or a follow-up cystoscopy are expected and settle on their own; others need the same-day attention of the urology team or an emergency department. Knowing the difference spares both needless worry and dangerous delay.

Seek urgent care if you cannot pass urine at all, or pass only a few drops with a full, painful bladder. Clots can block the outlet after resection, and a blocked bladder needs draining promptly. Heavy bleeding, meaning urine that looks like red wine rather than pink lemonade, that does not begin to clear after resting and drinking fluids, or that comes with large clots, also warrants a call.

Fever, shaking chills, or feeling suddenly unwell with flank or back pain can indicate a urinary infection or, after BCG treatment, a rare but serious body-wide reaction; the NHS advises contacting the care team without waiting. Severe lower abdominal pain, a swollen or rigid belly, or pain that worsens rather than eases in the days after surgery can signal a bladder wall injury and should be assessed the same day.

Between appointments, contact the team about new or returning blood in the urine once it had cleared, persistent burning beyond a couple of weeks, or any new symptom that concerns you. Recurrence is usually found at scheduled cystoscopy, but a symptom that appears between visits should not wait for the diary.

Keep the clinic’s direct number and the specialist nurse’s contact somewhere visible. These calls are expected, they are part of the follow-up plan, and the treating team would far rather hear from you early than late.

Frequently asked questions

Can bladder cancer come back after TURBT?

Yes, and for non-muscle-invasive disease this is common rather than unusual, which is why scheduled cystoscopy continues for years. Most recurrences are the same low stage and grade as the original tumor and are removed at a routine check. Progression to deeper or higher-grade disease is less common and concentrates in high-grade and T1 tumors, which receive the most intensive follow-up and treatment inside the bladder.

What is the follow-up protocol for bladder cancer after TURBT?

Follow-up is set by risk group. It typically combines cystoscopy every 3–6 months in the early years, urine cytology for higher-risk disease, periodic imaging of the kidneys and ureters where risk justifies it, and, for many people, chemotherapy or BCG placed into the bladder. Low-risk disease may be discharged from surveillance after a few clear checks; high-risk disease is often followed for many years. The treating team tailors the schedule.

How long for bladder biopsy results after TURBT?

Most reports are ready within about one to two weeks, though extra stains, a second pathologist’s review or discussion at a multidisciplinary meeting can extend this. The delay usually reflects careful reading of a borderline slide rather than bad news. Before leaving hospital, ask how results will be delivered and who to contact if nothing has been heard after the expected window.

How long does it take for the bladder to heal after a TURBT?

Surface healing takes several weeks, which is why the first follow-up cystoscopy is usually scheduled around three months later. Burning and urgency generally ease over one to two weeks, blood in the urine fades and may briefly return as the scab lifts, and heavy lifting is avoided for a few weeks. Most people are home the same day or after one night, with a catheter removed within a day or two.

Why do I need a follow-up cystoscopy after TURBT if the surgeon said it all came out?

Because the bladder lining can grow new tumors anywhere, not just where the last one was removed, and early recurrences cause no symptoms. The surgeon can confirm the visible tumor was resected; only regular inspection can confirm nothing new has appeared. Cystoscopy is the one test that reliably detects small low-grade recurrences, and urine tests alone are not a substitute.

What does it mean if my pathology report says no detrusor muscle was seen?

It means the sample did not include the bladder’s muscle layer, so the pathologist cannot confirm the tumor stopped short of it. For a tiny low-grade tumor this is often acceptable and deliberate. For high-grade or T1 disease it is a common reason for a second TURBT within a few weeks, so that depth can be assessed properly before the treatment plan is finalized.

Does needing a second TURBT mean the first operation went wrong?

No. A repeat resection is standard practice for high-grade T1 disease and for high-grade tumors where muscle was not sampled, because even well-performed first operations can leave residual tumor at the base or understage the disease. Guidance places it a few weeks after the first procedure. It is a planned quality step rather than a correction of an error.

What is bladder cancer recurrence after TURBT usually like when it is found?

Usually small and silent. Most recurrences are spotted at a scheduled cystoscopy as a tiny papillary growth or a subtle change at the old resection site, before any symptoms appear. They are typically removed by another resection, sometimes in clinic for very small lesions. The pathology from that recurrence is reviewed again, and the risk group and follow-up schedule may be adjusted accordingly.

Will I have BCG or chemotherapy into the bladder after TURBT?

That depends on your risk group and is decided by the treating urologist. Low- and intermediate-risk disease is often offered chemotherapy instilled into the bladder, sometimes as a one-time treatment shortly after surgery. High-risk disease and CIS are more commonly offered BCG, an immune-stimulating treatment given as an initial course and then maintenance. Neither replaces cystoscopy; surveillance continues alongside treatment.

How long is bladder cancer follow-up after TURBT, and does it ever stop?

It varies with risk. People with a single small low-grade tumor may be discharged from surveillance after a period of clear checks. Intermediate-risk disease is usually followed for around five years. High-risk disease is often monitored for many years, sometimes indefinitely, with visits spaced further apart over time. The schedule is reviewed at each visit, and the decision to stop rests with the treating team.

References

• NHS: Bladder cancer, Treatment
• NHS: Bladder cancer, Diagnosis
• MedlinePlus: Bladder Cancer
• MedlinePlus Medical Encyclopedia: Cystoscopy

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.